Atypical hemolytic uremic syndrome (aHUS) can occur as a rare complication of surgery involving the urinary tract, according to a report from Italy detailing the case of a woman in her 40s who developed the condition after undergoing a procedure to remove kidney stones. The patient, who had a…
News
A 38-year-old woman who developed pregnancy-associated atypical hemolytic uremic syndrome (P-aHUS) after giving birth via cesarean section successfully recovered following treatment with Soliris (eculizumab), a case report from China shows. Genetic testing revealed the presence of a mutation in the CFH gene, which likely contributed to her condition.
Short-term use of Soliris (eculizumab) in India — where the drug was approved just this year for treating two rare diseases — was effective for five children with atypical hemolytic uremic syndrome (aHUS), according to a new report. While the antibody therapy has been approved as an aHUS…
Adults with atypical hemolytic uremic syndrome (aHUS) who start Soliris (eculizumab) within seven days after their symptoms start see the best outcomes, a small real-world study in Western China suggests. The patients showed significantly improved blood and kidney function, and a reduced need for dialysis, while most given…
Atypical hemolytic uremic syndrome (aHUS) can occur concurrently with disseminated intravascular coagulation (DIC), a blood disorder marked by similar symptoms, but that has different underlying causes. The case of a boy with both aHUS and DIC was highlighted in the paper, “A Case Report of Atypical…
A 29-year-old woman in the U.S. showed signs of atypical hemolytic uremic syndrome (aHUS) and a C2 gene mutation, but without infection caused by Shiga toxin-producing Escherichia coli (STEC), according to a case report. STEC bacteria are the cause of the typical form of the disease. Genetic testing could…
Switching from Soliris (eculizumab) to Ultomiris (ravulizumab) is a safe and effective treatment strategy for people with atypical hemolytic uremic syndrome (aHUS), according to a real-world study in Japan. The treatment switch was associated with stable levels of blood and kidney-related disease markers, preventing disease relapse or…
More than half of Chinese children with atypical hemolytic uremic syndrome (aHUS) have self-reactive antibodies targeting complement factor H, a protein that regulates the activity of the immune complement cascade, a study showed. In turn, predisposing genetic mutations were detected in only 20% of the more than 100 children with aHUS…
Atypical hemolytic uremic syndrome (aHUS) may be triggered by acute inflammation of the pancreas, or pancreatitis, a team of researchers from India highlighted in a report describing the case of a 36-year-old man with both conditions. The man sought medical attention due to abdominal pain and was found to…
More than half of people with atypical hemolytic uremic syndrome (aHUS) in India have self-reactive antibodies targeting complement factor H (CFH), a protein that regulates the activity of the complement system, according to a recent study. These patients generally had better outcomes, being less likely to develop end-stage…
Recent Posts
- Boy’s kidney issues resolve after Soliris treatment: Case report
- I’m learning to say, ‘There’s always tomorrow’ when I’m feeling guilty
- Rare aHUS after kidney transplant successfully treated with Soliris
- Study describes ‘unusual trilogy’ of aHUS, Fabry disease, heart disorder
- My complicated health journey now includes post-exertional malaise
- Soliris part of strategy for complex kidney transplant in aHUS case
- My community helps me navigate the ultra-rare reality of living with aHUS
- Dual therapy manages aHUS with high blood pressure: Case report
- Caregivers are the unsung heroes of the rare disease world
- aHUS drug Soliris helps reverse organ failure in young woman in rare case